J Bone Miner Res. 2015 Dec;30 (12):2140-2149. doi: 10.1002/jbmr.2735. Epub 2018 Nov 4. Review. Collectively, this developing area of osteoimmunology raises new questions and promises to provide novel insights into pathophysiologic conditions as well as … Leer más
Calcif Tissue Int. 2015 Dec;97(6):551-9. doi: 10.1007/s00223-015-0046-x. Epub 2015 Aug 1. AI treatment in breast cancer patients is associated with deterioration of femoral cortical BMD and geometry, which could contribute in site-specific weakened bone strength … Leer más
La Fundación Española de Investigación Ósea y del Metabolismo Mineral (FEIOMM) convoca las BECAS FEIOMM-Movilidad con el fin de proporcionar una ayuda complementaria para la realización de estancias cortas en centros de investigación nacionales e … Leer más
PREVALENCIA DE OSTEOPOROSIS, FRACTURAS VERTEBRALES E HIPOVITAMINOSIS D EN MUJERES POSTMENOPÁUSICAS QUE VIVEN EN UN HÁBITAT RURAL Ver resolución aquí.
A raltegravir-based regimen was associated with significantly less loss of bone mineral density than a standard regimen containing tenofovir disoproxil fumarate, and might be a treatment option for patients at high risk of osteopenia or … Leer más
Our results suggest that serum levels of myostatin and irisin are related in patients with type 2 diabetes. Triglyceride and glucose levels could modulate myostatin and irisin concentrations as a compensatory mechanism to improve the … Leer más
These data show that the osteoprotegerin and receptor-activator of nuclear factor-κB ligand system is associated with bone markers and bone mineral density at the lumbar spine after obesity surgery.
Osteoporos Int. 2015 Nov;26(11):2561-72. doi: 10.1007/s00198-015-3250-7. Epub 2015 Jul 21. In particular, we discuss the close relationship between PBMs and osteoclasts, and highlight the utility of PBMs in study the pathophysiological mechanisms underlying various skeletal … Leer más
J Clin Endocrinol Metab. 2015 Nov;100(11):4208-14. doi: 10.1210/jc.2015-2829. Epub 2015 Sep 10 CONCLUSIONS: These findings lead us to conclude that premenopausal women with IOP, particularly those over 40, may require antiresorptive treatment to prevent bone … Leer más
Treatment with denosumab increases lumbar and femoral BMD and decreases bone turnover markers in individuals with recent SCI. This drug may be a promising therapeutic option in SCI-related osteoporosis.
